Annual report pursuant to Section 13 and 15(d)

Statements of Cash Flows

v3.8.0.1
Statements of Cash Flows - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2017
Dec. 31, 2016
Cash Flows from Operating Activities:    
Net loss $ (9,805) $ (3,926)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation 18 6
Stock-based compensation 707 324
Deferred compensation - related party 62 87
Change in fair value of warrant liability 2,548 0
Gain in settlement of liability (149) 0
Gain from expiration of warrants (1,238) 0
Other (9) 0
Changes in operating assets and liabilities:    
Prepaid expenses (364) (215)
Accounts payable 411 (41)
Accrued expenses 495 0
Net Cash Used in Operating Activities (7,324) (3,765)
Cash Flows from Investing Activities:    
Purchase of fixed assets (28) (21)
Acquisition of Moleculin, LLC, net 0 (100)
Net Cash Used in Investing Activities (28) (121)
Cash Flows from Financing Activities:    
Proceeds from notes payable 0 165
Payments on notes payable 0 (470)
Proceeds from exercise of warrants 3,988 0
Proceeds from sale of common stock, net of cash stock issuance costs 6,071 9,170
Net Cash Provided by Financing Activities 10,059 8,865
Net change in cash and cash equivalents 2,707 4,979
Cash and cash equivalents, at beginning of period 5,007 28
Cash and cash equivalents, at end of period 7,714 5,007
Supplemental disclosures of cash flow information:    
Cash paid for interest 3 5
Cash paid for income taxes 0 0
Supplemental disclosure of non-cash investing and financing activities:    
Common stock issued for the Acquisition of Moleculin, LLC 0 9,774
Common stock issued for conversion of debt 302 364
Warrants issued for services provided 104 375
Common stock issued for services provided $ 89 $ 158